Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinomaOlga Kondrashova, L. Green, Giada V. Zapparoli et al.|Nature Communications|2018Cited by 299
Prognostic gene expression signature for high-grade serous ovarian cancerJoshua Millstein, Scott D. Brown, Timothy Budden et al.|Annals of Oncology|2020Cited by 173
BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistanceKsenija Nešić, Harold C. Sullivan, John J. Krais et al.|Molecular Cancer|2024Cited by 28